Sampled properly last night in combination with 3FMC and bk-mdma. Brilliant stuff, very warm and lush, clean and friendly. Really boosts up the empathy and entactogenic quality's that can lack in bk-mdma and most definitely with 3-FMC.
Sounds like an amazing experience! How did you find the overall duration of the trip compared to when MDAI was absent?
Becoming recently aware of this study and thought I should post it here for others to check out.
"Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue.
Johnson MP, Huang XM, Nichols DE.
Department of Pharmacology and Toxicology, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN 47907. There is increasing evidence linking dopamine (DA) to the long-term serotonergic (5-HT) neurotoxic effects of certain substituted amphetamines such as 3,4-methylenedioxymethamphetamine (MDMA). The present study was undertaken to examine the importance of DA metabolism, uptake inhibition and release in the long-term effects of these drugs by combining various dopaminergic agents with an analogue of MDMA that had low neurotoxic liability, namely 5,6-methylenedioxy-2-aminoindan (MDAI). Monoamine and metabolite levels and the number of 5-HT uptake sites (using [3H]paroxetine binding) were determined 3 hours or 1 week after treatments. Combining the monoamine oxidase inhibitors, clorgyline (MAOA selective) or deprenyl (MAOB selective) with MDAI did not result in any long-term reductions of serotonergic markers. Similarly, combining the DA uptake inhibitor GBR-12909 with MDAI did not result in any long-term changes in monoamine levels at 1 week. In contrast, a single pretreatment of posttreatment with the nonvesicular DA releaser S-amphetamine and MDAI resulted in small but significant long-term changes in monoamine levels. More importantly, if a subacute dosing regimen (every 12 hours for 4 days) was utilized, the combination of S-amphetamine with MDAI resulted in a marked long-term decrease in the levels of cortical, hippocampal and striatal 5-HT, 5-HIAA and the number of 5-HT uptake sites. The results are discussed in terms of the significance of DA and especially nonvesicular DA release in the long-term effects of MDMA-like drugs."
Generally drawing on this it was recommended that if MDAI is to be combined with anything, it should rather be a dopamine reuptake inhibitor such as methylphenidate or MDPV than a dopamine releasers such as methylone/butylone/mephedrone/amphetamines etc.
What do others think of this study, would it affect your experiencing of this combo?
Although not in the same level of risk, my bad experience combining m1 and mephedrone in the past make me a little more wary of the m1 - MDAI combo.
Where do other's stand on the theory MDAI taken with M1 reduces the potential neuro-toxicity of M1 if taken by itself?